Literature DB >> 32453969

Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

M Patricia George1, Mark T Gladwin2,3, Brian B Graham4,5.   

Abstract

In this review, we explore the main themes from the 62nd Annual Aspen Lung Conference (hypoxia, cellular metabolism, inflammatory pathways, aberrant proliferation, and personalized medicine) and highlight challenges and opportunities in the coming decade of pulmonary vascular disease.

Entities:  

Keywords:  cellular proliferation; hypoxia signaling; personalized medicine; pulmonary hypertension

Mesh：

Year:  2020        PMID： 32453969      PMCID： PMC7462335          DOI： 10.1165/rcmb.2020-0099TR

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


  82 in total

1.  Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials.

Authors:  Julia A Beaver; Gwynn Ison; Richard Pazdur
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

2.  Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension.

Authors:  Dmitry A Goncharov; Elena A Goncharova; Stevan P Tofovic; Jian Hu; Jeff J Baust; Andressa Z Pena; Arnab Ray; Analise Rode; Rebecca R Vanderpool; Ana L Mora; Mark T Gladwin; Yen-Chun Lai
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

3.  Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension.

Authors:  Frédéric Perros; Peter Dorfmüller; David Montani; Hamida Hammad; Wim Waelput; Barbara Girerd; Nicolas Raymond; Olaf Mercier; Sacha Mussot; Sylvia Cohen-Kaminsky; Marc Humbert; Bart N Lambrecht
Journal:  Am J Respir Crit Care Med       Date:  2011-11-22       Impact factor: 21.405

4.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.

Authors:  Gianluigi Savarese; Stefania Paolillo; Pierluigi Costanzo; Carmen D'Amore; Milena Cecere; Teresa Losco; Francesca Musella; Paola Gargiulo; Caterina Marciano; Pasquale Perrone-Filardi
Journal:  J Am Coll Cardiol       Date:  2012-09-25       Impact factor: 24.094

5.  Loss of smooth muscle cell hypoxia inducible factor-1α underlies increased vascular contractility in pulmonary hypertension.

Authors:  Elizabeth A Barnes; Chih-Hsin Chen; Oshra Sedan; David N Cornfield
Journal:  FASEB J       Date:  2016-11-03       Impact factor: 5.191

6.  PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.

Authors:  Anna R Hemnes; Gerald J Beck; John H Newman; Aiden Abidov; Micheala A Aldred; John Barnard; Erika Berman Rosenzweig; Barry A Borlaug; Wendy K Chung; Suzy A A Comhair; Serpil C Erzurum; Robert P Frantz; Michael P Gray; Gabriele Grunig; Paul M Hassoun; Nicholas S Hill; Evelyn M Horn; Bo Hu; Jason K Lempel; Bradley A Maron; Stephen C Mathai; Mitchell A Olman; Franz P Rischard; David M Systrom; W H Wilson Tang; Aaron B Waxman; Lei Xiao; Jason X-J Yuan; Jane A Leopold
Journal:  Circ Res       Date:  2017-10-27       Impact factor: 17.367

7.  Hemodynamic improvement of pulmonary arterial hypertension after bariatric surgery: potential role for metabolic regulation.

Authors:  Meredith E Pugh; John H Newman; D Brandon Williams; Evan Brittain; Ivan M Robbins; Anna R Hemnes
Journal:  Diabetes Care       Date:  2013-03       Impact factor: 19.112

8.  Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Authors:  Zhiyu Dai; Maggie M Zhu; Yi Peng; Narsa Machireddy; Colin E Evans; Roberto Machado; Xianming Zhang; You-Yang Zhao
Journal:  Am J Respir Crit Care Med       Date:  2018-12-01       Impact factor: 30.528

9.  Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension.

Authors:  Samar Farha; Bo Hu; Suzy Comhair; Joe Zein; Raed Dweik; Serpil C Erzurum; Micheala A Aldred
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.